

POWERED BY COR2ED

## MEETING SUMMARY WCGIC 2020, VIRTUAL MEETING

#### **Dr Mohamed Bouattour**

Service d'Oncologie Digestive Hôpital BEAUJON, APHP, Clichy, France

HIGHLIGHTS FROM HCC CONNECT July 2020



**Please note:** Views expressed within this presentation are the personal opinions of the author. They do not necessarily represent the views of the author's academic institution or the rest of HCC CONNECT group.

This content is supported by an independent educational grant from Bayer.

**Disclosures:** Dr Mohamed Bouattour has received honoraria from the following: Bayer, BMS, Sirtex Medical, Roche, Eisai, AstraZeneca and Ipsen


# CHECKMATE 459: LONG-TERM SURVIVAL OUTCOMES WITH NIVOLUMAB VERSUS SORAFENIB AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA

Sangro B, et al. WCGIC 2020. Abstract #LBA-3. Oral presentation

### BACKGROUND



## **CheckMate 459 (NCT02576509):** randomised, stratified, multi-centre phase 3 study assessing nivolumab versus standard-of-care sorafenib in first line for advanced HCC



Primary analysis (database lock: June 2019): Median OS = 16.4 months for nivolumab vs 14.7 months for sorafenib with favourable and manageable safty profile<sup>1</sup>

The abstract presents long-term follow-up survival and safety data from CheckMate 459 (database lock: April 2020) with a minimum follow-up of 33.6 months

BID, twice daily; ECOG PS, Eastern cooperative oncology group performance status; FACT-Hep, functional assessment of cancer therapy- hepatobiliary cancer; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HRQOL; health-related quality of life; IV, intravenous; ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; q2w, every 2 weeks 1Yau T, et al. Ann Oncol 2019,30(suppl\_5):v851-v934

### **RESULTS: EFFICACY**



Overall survival	nivolumab (n=371)	sorafenib (n=372)	
Median OS, months (95% CI)	16.4 (14.0-18.5)	14.8 (12.1-17.3)	
HR (95% CI)	0.85 (0.72-1.00); p=0.0522		
Overall survival by PD-L1 expression			
Median OS in tumour cell PD-L1 $\ge$ 1%, months (95% CI)	16.1 (8.4-22.3)	8.6 (5.7-16.3)	
HR (95% CI)	0.80 (0.54-1.17)		
Median OS in tumour cell PD-L1 < 1%, months (95% CI)	16.7 (13.9-19.4)	15.2 (12.7-18.1)	
HR (95% CI)	0.84 (0.70-1.01)		
Overall survival by aetiology			
Median OS in HCV patients, months (95% CI)	17.5 (13.9-21.9)	12.7 (9.9-16.2)	
HR (95% CI)	0.72 (0.51-1.02)		
Median OS in HBV patients, months (95% CI)	16.1 (12.5-21.3)	10.4 (8.5-17.3)	
HR (95% CI)	0.79 (0.59-1.07)		
Median OS in uninfected patients, months (95% CI)	16.0 (10.8-20.2)	17.4 (13.7-21.3)	
HR (95% CI)	0.91 (0.72-1.16)		


CI, confidence interval; HR, hazard ratio; HBC, hepatitis B virus; HCV, hepatitis C virus; OS, overall survival; PD-L1, programmed death ligand 1

### **RESULTS: EFFICACY (CON'T) AND SAFETY**



OS rate (%)		nivolumab	sorafenib
	12-month	60%	55%
	24-month	37%	33%
	33-month	29%	21%

• Events occurring in > 10% of patients in either treatment arm are presented:



OS, overall survival; NIVO, nivolumab; SOR, sorafenib; TRAE, treatment-related adverse event

### CONCLUSIONS



## **CheckMate 459 study did not meet its primary endpoint;** however, in this long-term analysis, the authors showed that:

- Median OS : 16.4 months for nivolumab vs 14.8 months for sorafenib
- Median OS longer with nivolumab vs sorafenib in HCV and HBV groups
- Median OS is consistently beneficial with nivolumab regardless of PD-L1 expression
- Nivolumab has a more favourable safety profile than sorafenib with:
  - Grade 3-4 TRAEs: 22% for nivolumab vs 50% for sorafenib
  - TRAEs leading to discontinuation: 8% with nivolumab vs 11% with sorafenib
  - Liver function preservation over time in the nivolumab arm compared with sorafenib arm


ATEZOLIZUMAB + BEVACIZUMAB VS SORAFENIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC): RESULTS FROM OLDER ADULTS ENROLLED IN IMBRAVE150

> Li D, et al. WCGIC 2020. Abstract #O-8. Oral presentation

### TRIAL DESIGN



**IMbrave150 (NCT03434379):** Randomised phase 3 trial assessing combination therapy with the PD-L1 inhibitor atezolizumab and the VEGF inhibitor bevacizumab versus standard-of-care sorafenib in first line for advanced HCC



AFP, alpha-fetoprotein; BID, twice a day; ECOG PS; Eastern Cooperative Oncology Group performance status; HCC, hepatocellular carcinoma; IRF, independent review facility; IV, intravenous; (m)RECIST, (modified) Response Evaluation Criteria In Solid Tumours; ORR, objective response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PRO, patient-reported outcome; q3w, every 3 weeks; QoL, quality of life; R, randomisation; VEGF, vascular endothelial growth factor Finn RS, et al. N Engl J Med 2020;382:1894-905

#### **RESULTS: EFFICACY**



• Data cut-off date: 29 August 2019; median survival follow-up: 8.6 months

	<65 years		≥65 years	
	atezolizumab + bevacizumab (n=175)	sorafenib (n=74)	atezolizumab + bevacizumab (n=161)	sorafenib (n=91)
Median OS, months	NE	11.4	NE	14.9
OS, HR (95% CI)	0.59 (0.38-0.91)		0.58 (0.36-0.92)	
Median PFS per IRF RECIST v1.1, months	6.7	2.9	7.7	4.8
PFS, HR (95% CI)	0.50 (0.36-0.71)		0.63 (0.45-0.89)	
Response-evaluable population, n	171	70	155	89
ORR per IRF RECIST v1.1, n (%)	49 (29)	7 (10)	40 (26)	12 (13)
CR, n (%)	11 (6)	0	7 (5)	0

CI, confidence interval; CR, complete response; HR, hazard ratio; IRF, independent review facility; NE, not evaluable; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumours



	atezolizumab + bevacizumab		
	<65 years (n=171)	≥65 years (n=158)	
Grade 3-4 AEs, n (%)	92 (54)	94 (59)	
Treatment-related grade 3-4 AEs, n (%)	55 (32)	62 (39)	
Grade 5 AEs, n (%)	7 (4)	8 (5)	
Treatment-related grade 5 AEs, n (%)	2 (1)	4 (3)	
AEs leading to withdrawal from any components, n (%)	21 (12)	30 (19)	
AEs leading to withdrawal from both components, n (%)	9 (5)	14 (9)	

### CONCLUSIONS



#### ATEZOLIZUMAB + BEVACIZUMAB: APPROVED BY US FDA ON 29 MAY 2020 AS FIRST-LINE SYSTEMIC THERAPY FOR ADVANCED HCC

- Analysis of older patients (≥65 years) from IMbrave150 demonstrated that:
  - OS, PFS and ORR benefits are consistent across ages
  - Safety profile is consistent across age groups with no significant additional toxicities. However due to the specific eligibility criteria for the trial population, safety in a broader population warrants further study


 These data show that older patients (≥65 years) with advanced HCC could benefit from the combination treatment in 1L setting OUTCOMES FOR PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND CHILD-PUGH B LIVER FUNCTION IN THE PHASE 3 CELESTIAL STUDY OF CABOZANTINIB VS PLACEBO

> El-Khoueiry A, et al. WCGIC 2020, Abstract #SO-9. Oral presentation

### **TRIAL DESIGN**



# **CELESTIAL (NCT01908426):** Randomised double-blind controlled phase 3 trial assessing cabozantinib vs placebo in previously treated patients with advanced HCC



The abstract presents a retrospective analysis of data from patients with Child-Pugh B by week 8 from the CELESTIAL study

ECOG PS; Eastern Cooperative Oncology Group performance status; HBV, hepatitis B virus; HCC; hepatocellular carcinoma; HCV, hepatitis C virus; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PO, per os; qd, once a day; R, randomisation

#### **RESULTS: EFFICACY**



• At Week 8, 51/470 patients in the cabozantinib arm and 22/237 patients in the placebo arm had investigator-assessed Child-Pugh B cirrhosis

	Child-Pugh B subgroup		Overall	
	cabozantinib (n=51)	placebo (n=22)	cabozantinib (n=470)	placebo (n=237)
Median OS, months (95% CI)	8.5 (7.7-12.2)	3.8 (3.3-4.8)	10.2 (9.1-12.0)	8.0 (6.8-9.4)
OS, HR (95% CI)	0.32 (0.18-0.58)		0.76 (0.63-0.92); p=0.005	
Median PFS, months (95% CI)	3.7 (1.9-5.2)	1.9 (1.7-2.1)	5.2 (4.0-5.5)	1.9 (1.9-1.9)
PFS, HR (95% CI)	0.44 (0.25	-0.76)	0.44 (0.36-0.5	2); p<0.001



	cabozantinib arm*		
	Child-Pugh B subgroup (n=51)	Overall (n=467)	
Median duration of exposure (range), months	3.7 (1.4-12.9)	3.8 (0.1-37.3)	
Dose reduction, %	61	62	
Discontinuation due to treatment-related AE, %	18	16	
All causality Grade 3-4 AEs, %	71	68	
Fatigue	20	10	
Ascites	14	4	
Aspartate aminotransferase increase	14	12	
Thrombocytopenia	12	3	
Palmar-plantar erythrodysesthesia	8	17	
Hypertension	8	16	

#### CONCLUSIONS



- Retrospective exploratory analysis of patients with Child-Pugh B by week 8 from CELESTIAL study showed that:
  - cabozantinib has a manageable safety profile in this subgroup
  - efficacy data for OS and PFS suggest clinical benefit in this subgroup
- These data show that further clinical trials investigations are needed in Child-Pugh B patients with HCC to fill the high unmet medical need for this population

### REACH HCC CONNECT VIA TWITTER, LINKEDIN, VIMEO & EMAIL OR VISIT THE GROUP'S WEBSITE http://www.hccconnect.info





**HCC CONNECT** 



Email froukje.sosef@cor2ed.com



HCC CONNECT Bodenackerstrasse 17 4103 Bottmingen SWITZERLAND

#### Dr. Froukje Sosef MD

 $\sim$ 

 $\sim$ 

+31 6 2324 3636

froukje.sosef@cor2ed.com

#### Dr. Antoine Lacombe Pharm D, MBA



antoine.lacombe@cor2ed.com



#### Heading to the heart of Independent Medical Education Since 2012